Jon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026

Fewer than one in ten eligible CAR-T patients ever receives the therapy. For Trenchant BioSystems CEO Jon Ellis, that single statistic reframes the whole field: while the science increasingly works — the cost to tailor a treatment to each patient is too high, putting it out of reach for most of the world. • Ellis spent more than two decades in the field, from cord blood and stem-cell transplantation in the UK's NHS to a decade developing products and consulting for big pharma in the US. Then consulting made the crucial gap obvious: "there wasn't a band-aid big enough" to fix cell therapy manufacturing. And so he co-founded Trenchant to fix it. • The headline target is manufacturing in about 2.5 days. Trenchant's proprietary process doesn't lose cells along the way, which reduces or removes the need to expand them at the end and cuts the vein-to-vein time for end-stage cancer patients who can't afford to wait. • Trenchant can't change a therapy's price, but slashing the cost of making it is what could open access to academic centres and the developing world, instead of leaving cell therapy a first-world solution. • Real automation needs biology, hardware and software as one system. Trenchant pairs with Autolomous on digital manufacturing management and with Invetech as development partner, building its products across San Diego and Melbourne for launch next year. • A point-of-care collaboration with UMass and Caring Cross targets gene-edited CD34 stem-cell therapies for sickle cell disease — most common in an underserved, underinsured population Ellis calls the most thrilling work of his life — aiming to take manufacturing from months to days. • The aspiration he keeps returning to: a patient walks in, is treated, and goes home the same day. Onyx caught up with Jon Ellis, CEO of Trenchant BioSystems, at the International Society for Cell & Gene Therapy 2026 Annual Meeting in Dublin to talk about faster, cheaper manufacturing, point-of-care for sickle cell, and why access — not science — is now the field's defining challenge. With thanks to the International Society for Cell & Gene Therapy for welcoming Onyx Live to Dublin.